2.50
Hdl Handle:
http://hdl.handle.net/10541/72581
Title:
Management of advanced colorectal cancer: state of the art.
Authors:
Saunders, Mark P; Iveson, T
Abstract:
Colorectal cancer (CRC) caused over 500 000 deaths worldwide in 2002. Recent advances in the treatment of advanced disease include the incorporation of two new cytotoxic agents, irinotecan and oxaliplatin, into first-line regimens. The concept of planned sequential therapy involving three active agents during the course of a patient's treatment is evolving. Coupled with the integrated use of targeted monoclonal antibodies, we can now expect overall survival rates for advanced disease to exceed 20 months. This review considers current treatments and suggests where future progress may occur.
Affiliation:
Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. mark.saunders@christie-tr.nwest.nhs.uk
Citation:
Management of advanced colorectal cancer: state of the art. 2006, 95 (2):131-8 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
17-Jul-2006
URI:
http://hdl.handle.net/10541/72581
DOI:
10.1038/sj.bjc.6603233
PubMed ID:
16835584
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorSaunders, Mark P-
dc.contributor.authorIveson, T-
dc.date.accessioned2009-07-06T12:07:30Z-
dc.date.available2009-07-06T12:07:30Z-
dc.date.issued2006-07-17-
dc.identifier.citationManagement of advanced colorectal cancer: state of the art. 2006, 95 (2):131-8 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid16835584-
dc.identifier.doi10.1038/sj.bjc.6603233-
dc.identifier.urihttp://hdl.handle.net/10541/72581-
dc.description.abstractColorectal cancer (CRC) caused over 500 000 deaths worldwide in 2002. Recent advances in the treatment of advanced disease include the incorporation of two new cytotoxic agents, irinotecan and oxaliplatin, into first-line regimens. The concept of planned sequential therapy involving three active agents during the course of a patient's treatment is evolving. Coupled with the integrated use of targeted monoclonal antibodies, we can now expect overall survival rates for advanced disease to exceed 20 months. This review considers current treatments and suggests where future progress may occur.en
dc.language.isoenen
dc.subjectColorectal Canceren
dc.subject.meshAntineoplastic Agents-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshDisease Progression-
dc.subject.meshDrug Therapy, Combination-
dc.subject.meshHumans-
dc.subject.meshSurvival Rate-
dc.titleManagement of advanced colorectal cancer: state of the art.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. mark.saunders@christie-tr.nwest.nhs.uken
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.